Officials with The Medicines Company announced that the Food and Drug Administration has approved Ionsys (fentanyl iontophoretic transdermal system) for the short-term management of acute post-operative pain in adults requiring opioid analgesia in the hospital. Ionsys is the first needle-free, patient-controlled pre-programmed fentanyl delivery system to be approved.
Ionsys, a CII controlled substance, allows patients to control their analgesic dosing by pushing a button to administer fentanyl transdermally via an imperceptible electrical current as needed for pain. Ionsys contains fentanyl, an opioid analgesic that interacts predominately with the opioid mu-receptor. These mu-binding sites are distributed in human brain, spinal cord, and other tissues.
The efficacy of Ionsys was demonstrated in three placebo-controlled trials. The safety of Ionsys was established in three placebo-controlled trials and four additional active-controlled randomized trials.
Ionsys can only be dispensed to patients in hospitals enrolled in the Ionsys Risk Evaluation Mitigation Strategy (REMS) program; it is not intended for home use. Ionsys is expected launch in the third quarter of 2015.
This article originally appeared on MPR